
Uday R Popat, M.D.
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
About Dr. Popat
Dr. Uday Popat graduated from the Lokmanya Tilak Municipal Medical College in Bombay, India. He completed the residency and fellowship programs at institutions in the United Kingdom, India and the United States including Baylor College of Medicine and The University of Texas MD Anderson Cancer Center. He is currently Professor of Medicine in the department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center.
Present Title & Affiliation
Primary Appointment
Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Myelofibrosis: Reduced intensity allogeneic transplantation(SCT) for myelofibrosis: This is a novel study, first protocol in this disease at MDACC and the largest single center study, which is still accruing patients. Our preliminary results are encouraging. If these hold over a period of time, this should become standard of care and establish allogeneic transplant as a viable, curative therapy. In a separate study we showed that long term remission was possible in patients with AML post MF after SCT. This finding has not been previously reported.
Multiple Sclerosis: My previous study and current ongoing study at MDACC will go some way in establishing a role for autologous transplantation in this disease. Our study on allogeneic transplantation for patients with ALS was novel and although negative for clinical endpoints did show significant trafficking of donor hematopoietic stem cells to diseased areas in central nervous system.
Imapct of comorbidities on SCT: To identify patients most suitable for allo transplant and to identify the most suitable transplant strategy for patients with comorbidities.
Risk factors predicting stem cell mobilization failure.Education & Training
Degree-Granting Education
2016 | Rice University, Houston, TX, USA, MBA, Business Administration |
2003 | Royal College of Pathologists, London, GBR, FRCPath, Hematology |
1995 | Royal College of Pathologists, London, GBR, MRCPath, Hematology |
1994 | Royal College of Pathologists, London, GBR, Dip RCPath, Hematology |
1991 | Royal College of Physicians, London, GBR, MRCP, Internal Medicine |
1988 | University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bomabay, IND, MD, Internal Medicine |
1983 | University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bombay, IND, MB, BS, Med School |
Postgraduate Training
1997-1999 | Residency, Internal Medicine, Baylor College of Medicine, Houston, TX |
1996-1997 | Fellowship, Hematology and Medical Oncology, Baylor College of Medicine, Houston, TX |
1995-1996 | Fellowship, Bone Marrow Transplant, The University of Texas MD Anderson Cancer Center, Houston, TX |
1994-1995 | Fellowship, Bone Marrow Transplant, Royal Free Hospital and School of Medicine University of London, London |
1983-1988 | Internship and Residency, Internal Medicine, Lokmanya Tilak Municipal Medical College and General Hospital, University of Bombay, Bombay |
Board Certifications
2001 | American Board of Internal Medicine, Medical Oncology |
2001 | American Board of Internal Medicine, Hematology |
2000 | American Board of Internal Medicine, Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2011
Administrative Appointments/Responsibilities
Associate Program Director, Department of Stem Cell Transplant Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present
Institutional Committee Activities
Member, Search committee for Neuro onc, 2019 - Present
Member, Operative task force 6, 2019 - Present
Member, Urgent care task force, 2019 - Present
Member, Cost accounting committee, 2019 - Present
Member, Executive Committee of Medical Staff, 2018 - Present
Member, TMC 2 Taskforce, 2017 - Present
Member, PRS Faculty Compensation & Benefit Advisory Committee, 2017 - Present
Member, Operational Priority 2 Financial Sustainability, 2017 - Present
Member, Executive Institutional Compliance Committee, 2017 - 2018
Member, Faculty Senate Executive Committee, 2015 - 2017
Member, Credentials Committee of the Medical Staff, 2015 - Present
Quality Officer, Quality Officer for Stem Cell Transplantation and Cellular Therapy, 2011 - Present
Member, Clinical Research Committee - CRC 2, 2011 - 2015
Alternate Member, Credentials Committee of the Medical Staff, 2011 - 2015
Member, Computerized Provider Order Entry (CPOE) Steering Committee, 2010 - Present
Member, Faculty Senate, 2010 - 2018
Member, Infection Control Committee, 2008 - 2013
Member, Infection Control Core Group, 2008 - 2013
Honors & Awards
2020 | Best Abstract Award, 2020 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR |
2009 | Best Doctors in America, Best Doctors, Inc |
Selected Publications
Peer-Reviewed Articles
- Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
- Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica 104(12):e555-e557, 2019. e-Pub 2019. PMID: 30948491.
- Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol 183(5):831-835, 2018. e-Pub 2017. PMID: 29265180.
- Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. PMID: 30389035.
- Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology 88(9):842-852, 2017. e-Pub 2017. PMID: 28148635.
- Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant 22(3):432-40, 2016. e-Pub 2015. PMID: 26493563.
- Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD. High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report. JAMA Neurol 72(2):159-69, 2015. e-Pub 2014. PMID: 25546364.
- Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 2013. e-Pub 2012. PMID: 23128322.
- Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 2011. e-Pub 2011. PMID: 21948087.
- Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat U. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 16(4):555-9, 2010. e-Pub 2010. PMID: 20005966.
- Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 2009. e-Pub 2009. PMID: 19654407.
- Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. Biol Blood Marrow Transplant 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
- Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 2009. e-Pub 2009. PMID: 19384931.
- Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9(3):S261-5, 2009. PMID: 19778850.
- Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 71(17):1326-34, 2008. PMID: 18936424.
- Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL negative myeloproliferative neoplasms. Blood 112(5):1628-37, 2008. e-Pub 2008. PMID: 18566326.
- Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA. Autologous HSCT for advanced MS: is the glass half-empty or really half-full?. Brain 131(Pt 2):e89, 2008. e-Pub 2007. PMID: 17908695.
- Samuelson SJ, Popat U, Prchal JT. Marrow fibrosis does not account for circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Haematologica 92(4 e47):ELT02, 2007. PMID: 17405759.
- Popat U, Frost A, Liu E, Guan Y, Durette A, Reddy V, Prchal JT. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood 107(9):3486-3488, 2006. e-Pub 2006. PMID: 16418333.
- Popat U, Heslop HE, Durett A, May R, Krance RA, Brenner MK, Carrum G. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant 37(6):547-52, 2006. PMID: 16462757.
- Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, Land GA, Heslop H, Brenner M, Zhang JZ. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 127(Pt 5):996-1008, 2004. e-Pub 2004. PMID: 14985264.
Invited Articles
- Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev 29(1):3-10, 2003. PMID: 12633575.
Abstracts
- Popat U, Bassett R, Aung F, Valdez B, Ahmed S, Alousi A, Bashir Q, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash M, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson B, Champlin R. Eltrombopag to improve platelet recovery in haploidentical stem cell transplants (Haplo-SCT): Results of a Phase II Trial Plus a Comparison to Control Patients. HemaSphere 23rd EHA Congress, 2018.
- Popat UR, Saliba R, Oran B, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Valdez B, Jones RB, Shpall EJ, Andersson B, Champlin RE. Better Survival With Fludarabine And Timed Sequential Busulfan Regimen In Older Patients with AML/MDS. J Clin Oncol 2017 ASCO Annual Meeting 35(15_suppl):7046, 2017.
Book Chapters
- Fanale M, Dabaja B, Popat U, Anderlini P, Younes A. Hodgkin Lymphoma. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer Science, 225-239, 2012.
- Rice L, Popat U. Non-Hodgkin's Lymphoma. In: Conn's Current Therapy 2008. Saunders-Elsevier: United Kingdom, 458-461, 2008.
- Popat U, Giralt S. Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia. In: Contemporary Hematology, Stem Cell Transplantation for Hematoligic and other Disorders. Humana Press: Totowa, NJ, 2008.
- Popat U, Giralt S. Hematopoietic cell transplantation for chronic myeloid leukemia and myelofibrosis. In: Chronic Myeloproliferative Disorders. Informa Press, 2008.
Grant & Contract Support
Title: | High dose immunosuppression and autologous transplantation for multiple sclerosis (HALT MS) study |
Funding Source: | NIH/NCI |
Role: | Principal Investigator-MDACC |
Title: | Eltrombopag for post transplant thrombocytopenia |
Funding Source: | GlaxoSmithKline |
Role: | Principal Investigator |
Title: | Allogeneic stem cell transplantation for myelofibrosis using reduced intensity busulfan and fludarabine conditioning |
Funding Source: | Otsuka Pharmaceutical Company Ltd |
Role: | Principal Investigator |
Title: | Novel Correlative Studies for Ongoing MD Anderson Eltrombopag Trials |
Funding Source: | Novartis |
Role: | Co-Investigator |
Title: | Pacritinib Prior to Transplant for Patients with Myeloproliferative Neoplasms (MPN) |
Funding Source: | CTI BioPharma Corp |
Role: | Principal Investigator |
Title: | Blu/Flu and Sorafenib in AML/MDS |
Funding Source: | Bayer Pharmaceutical |
Role: | Principal Investigator |